Zurcher Kantonalbank (Zurich Cantonalbank) Eq Rx, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	BUY	$1.66 - $2.31 $66,665 - $92,769	40,160 Added 199.42%	60,298 $133,000
Q4 2022 Feb 01, 2023	BUY	$2.05 - $5.5 $6,289 - $16,874	3,068 Added 17.97%	20,138 $49,000
Q2 2022 Aug 09, 2022	BUY	$3.2 - $5.69 $54,624 - $97,128	17,070 New	17,070 $80,000

Others Institutions Holding EQRX

# of Institutions

Shares Held

67.8M

Call Options Held

Put Options Held

Ah Equity Partners Bio Iii, L.L.C. Menlo Park, CA

19.2M
Shares

$0
100.0% of portfolio
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA

17.4M
Shares

$0
60.15% of portfolio
Arboretum Ventures, Inc.

13.9M
Shares

$0
63.96% of portfolio
Ah Equity Partners Lsv I, L.L.C. Menlo Park, CA

11.4M
Shares

$0
8.42% of portfolio
Ah Equity Partners Lsv Ii, L.L.C. Menlo Park, CA

5M
Shares

$0
11.61% of portfolio

View Full List

About EQRx, Inc.

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

More about EQRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account